tradingkey.logo
tradingkey.logo
Search

Bioventus Inc

BVS
Add to Watchlist
10.480USD
+0.630+6.40%
Close 07/02, 13:00ETQuotes delayed by 15 min
703.18MMarket Cap
24.52P/E TTM

More Details of Bioventus Inc Company

Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.

Bioventus Inc Info

Ticker SymbolBVS
Company nameBioventus Inc
IPO dateFeb 11, 2021
CEOClaypoole (Robert E)
Number of employees930
Security typeOrdinary Share
Fiscal year-endFeb 11
Address4721 Emperor Boulevard, Suite 100
CityDURHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code27703
Phone19194746700
Websitehttps://www.bioventus.com/
Ticker SymbolBVS
IPO dateFeb 11, 2021
CEOClaypoole (Robert E)

Company Executives of Bioventus Inc

Name
Name/Position
Position
Shareholding
Change
Ms. Susan M. Stalnecker
Ms. Susan M. Stalnecker
Independent Director
Independent Director
138.24K
+23.35%
Mr. Guido J. Neels
Mr. Guido J. Neels
Independent Director
Independent Director
117.52K
+27.47%
Mr. John A. Bartholdson
Mr. John A. Bartholdson
Independent Director
Independent Director
111.90K
+28.85%
Mr. Patrick J. (Pat) Beyer
Mr. Patrick J. (Pat) Beyer
Independent Director
Independent Director
108.72K
+29.69%
Mr. Philip G. Cowdy
Mr. Philip G. Cowdy
Independent Director
Independent Director
32.28K
--
Mr. Anthony D'adamio, J.D.
Mr. Anthony D'adamio, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Ms. Katrina Church, J.D.
Ms. Katrina Church, J.D.
Senior Vice President, Chief Compliance Officer
Senior Vice President, Chief Compliance Officer
--
--
Mr. William A. (Bill) Hawkins, III
Mr. William A. (Bill) Hawkins, III
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Guy Paul Nohra
Mr. Guy Paul Nohra
Independent Director
Independent Director
--
--
Marty Sutter ,
Marty Sutter ,
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Susan M. Stalnecker
Ms. Susan M. Stalnecker
Independent Director
Independent Director
138.24K
+23.35%
Mr. Guido J. Neels
Mr. Guido J. Neels
Independent Director
Independent Director
117.52K
+27.47%
Mr. John A. Bartholdson
Mr. John A. Bartholdson
Independent Director
Independent Director
111.90K
+28.85%
Mr. Patrick J. (Pat) Beyer
Mr. Patrick J. (Pat) Beyer
Independent Director
Independent Director
108.72K
+29.69%
Mr. Philip G. Cowdy
Mr. Philip G. Cowdy
Independent Director
Independent Director
32.28K
--
Mr. Anthony D'adamio, J.D.
Mr. Anthony D'adamio, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--

FAQs

Who are the top five shareholders of Bioventus Inc?

The top five shareholders of Bioventus Inc are: Ms. Susan M. Stalnecker

How many institutions hold shares of Bioventus Inc (BVS)?

As of 2026Q1, 339 institutions hold shares of Bioventus Inc, with a combined market value of approximately 52.51M, accounting for 77.51% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -10203484.00.

What is the biggest source of revenue for Bioventus Inc?

In 2026Q1, the Pain Treatments business generated the highest revenue for Bioventus Inc, amounting to 279.06M and accounting for 49.12% of total revenue.